I am recently running into this field. I read several review papers and some claim that cMET inhibitor achieve promising Clinical activity with an acceptable toxicity. The other paper said None o f the HGF/cMET inhibitors have shown significant efficacy in clinical trials and no RTK inhibitors primarily targeting cMET have been approved. Which one is correct? I hope experts in cMET field provide some update. Thanks in advance.